Skip to main content
SpringerLink
Log in

Development of Antiviral Therapy for Chronic Infection with Hepatitis B Virus

  • Chapter
Hepadnaviruses

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 168))

  • 148 Accesses

Abstract

Infection with hepatitis B virus (HBV) can now be prevented through the use of several effective vaccines (Maynard et al. 1989). Yet for the millions of existing chronic carriers there is no effective treatment to clear the virus and thus limit the high risk of liver diseases associated with long-term infection; chronic hepatitis, cirrhosis, and hepatocellular carcinoma. A number of recent reviews have described the limited success of current antiviral therapies of patients chronically infected with hbv (Alexander and Williams 1988; Lever 1988; Garcia and Gentry 1989; Di Bisceglie and Hoofnagle 1989). The focus of this chapter will be on understanding why HBV is difficult to eradicate once chronic infection is established, on possible new targets for antiviral therapy in the life cycle of HBV, and on recently developed models for testing the efficacy of anti-hepadnaviral treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adam SA, Lobl TJ, Mitchell MA, Gerace L (1989) Identification of specific binding proteins for a nuclear location sequence. Nature 337: 276–279

    Article  PubMed  CAS  Google Scholar 

  • Agarwal S, Ikeuchi T, Sun D, Sarin PS, Konopka A, Maizel J, Zamecnik PC (1989) Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxy-nucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA 86: 7790–7794

    Article  Google Scholar 

  • Albin C, Robinson WS (1980) Protein kinase activity in hepatitis B virus. J Virol 34: 297–302

    PubMed  CAS  Google Scholar 

  • Aldrich CE, Coates L, Wu TT, Newbold J, Tennant BC, Summers J, Seeger C, Mason WS (1989) In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus. Virology 172: 247–252

    Article  PubMed  CAS  Google Scholar 

  • Alexander GJ, Williams R (1988) Natural history and therapy of chronic hepatitis B virus infection. Am J Med 85: 143–146

    Article  PubMed  CAS  Google Scholar 

  • Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, Matsubara K, Yamamura K (1989) Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 86: 207–211

    Article  PubMed  CAS  Google Scholar 

  • Bartenschlager R, Schaller H (1988) The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J 7:4185–4192

    PubMed  CAS  Google Scholar 

  • Beasley RP, Hwang LY (1984) Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, New York, pp 209–224

    Google Scholar 

  • Brook MG, Karayiannis P, Thomas HC (1989) Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10:761–763

    Article  PubMed  CAS  Google Scholar 

  • Burk RD, DeLoia JA, elAwady MK, Gearhart JD (1988) Tissue preferential expression of the hepatitis B virus (HBV) surface antigen gene in two lines of HBV transgenic mice. J Virol 62: 649–654

    PubMed  CAS  Google Scholar 

  • Canonico PG, Kende M, Gabrielsen B (1988) Carrier-mediated delivery of antiviral agents. Adv Virus Res 35:271–312

    Article  PubMed  CAS  Google Scholar 

  • Chen PJ, Chen CR, Sung JL, Chen DS (1989) Identification of a doubly spliced viral transcript joining the separated domains for putative protease and reverse transcriptase of hepatitis B virus. J Virol 63:4165–4171

    PubMed  CAS  Google Scholar 

  • Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL (1987) Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 84: 6909–6913

    Article  PubMed  CAS  Google Scholar 

  • Cohen EA, Gaudreau P, Brazeau P, Langelier Y (1986) Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2. Nature 321: 441–443

    Article  PubMed  CAS  Google Scholar 

  • Diana GD, Pevear DC, Otto MJ, McKinlay MA, Rossmann MG, Smith T, Badger J (1989) Inhibitors of viral uncoating. Pharmacol Ther 42: 289–305

    Article  PubMed  CAS  Google Scholar 

  • Di Bisceglie AM, Hoofnagle JH (1989) Treatment of chronic type B hepatitis, Cancer Detection and Prevention 14: 291–293

    PubMed  Google Scholar 

  • Dunsford HA, Sell S, Chisari FV (1990) Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Research 50: 3400–3407

    PubMed  CAS  Google Scholar 

  • Enders GH, Ganem D, Varmus HE (1987) 5′-terminal sequences influence the segregation of ground squirrel hepatitis virus RNAs into polyribosomes and viral core particles. J Virol 61: 35–41

    PubMed  CAS  Google Scholar 

  • Farza H, Hadchouel M, Scotto J, Tiollais P, Babinet C, Pourcel C (1988) Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome. J Virol 62: 4144–4152

    PubMed  CAS  Google Scholar 

  • Fiume L, Bassi B, Busi C, Mattioli A, Spinosa G (1986) Drug targeting in antiviral chemotherapy. Biochem Pharmacol 35: 967–972

    Article  PubMed  CAS  Google Scholar 

  • Francois JC, Saison-Behmoaras T, Barbier C, Chassignol M, Thuong NT, Helene C (1989) Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate. Proc Natl Acad Sci USA 86: 9702–9706

    Article  PubMed  CAS  Google Scholar 

  • Galle PR, Schlicht HJ, Kuhn C, Schaller H (1989) Replication of duck hepatitis B virus in primary duck hepatocytes and its dependence on the state of differentiation of the host cell. Hepatology 10: 459–465

    Article  PubMed  CAS  Google Scholar 

  • Ganem D, Varmus HE (1987) The molecular basis of the hepatitis B viruses. Annu Rev Biochem 56: 651–693

    Article  PubMed  CAS  Google Scholar 

  • Garcia G, Gentry KR (1989) Chronic viral hepatitis. Med Clin North Am 73: 971–983

    PubMed  CAS  Google Scholar 

  • Gartner TK, Bennett JS (1985) The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 260: 11891–11894

    PubMed  CAS  Google Scholar 

  • Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C (1988) Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 62:4136–4143

    PubMed  CAS  Google Scholar 

  • Haseltine WA (1989) Development of antiviral drugs for the treatment of AIDS: strategies and prospects. J Acquired Immune Deficiency Syndromes 2: 311–334

    CAS  Google Scholar 

  • Herschlag D, Cech, TR (1990) DNA cleavage catalysed by the ribozyme from Tetrahymena. Nature 344: 405–409

    Article  PubMed  CAS  Google Scholar 

  • Herskowitz I (1987) Functional inactivation of genes by dominant negative mutations. Nature 329 : 219–222

    Article  PubMed  CAS  Google Scholar 

  • Hirota K, Sherker AH, Omata M, Yokosuka O, Okuda K (1986) Effects of adenine arabinoside and corticosteroid on replication of duck hepatitis B virus DNA in the liver. Ann Acad Med Singapore 15:227–232

    PubMed  CAS  Google Scholar 

  • Hirota K, Sherker AH, Omata M, Yokosuka O, Okuda K (1987) Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection. Hepatology 7: 24–28

    Article  PubMed  CAS  Google Scholar 

  • Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Buskell Bales Z (1981) Seroconversion from hepatitis B virus e antigen to antibody in chronic type B hepatitis. Ann Intern Med 94: 744–748

    PubMed  CAS  Google Scholar 

  • Jean-Jean O, Salhi S, Carlier D, Elie C, De Recondo AM, Rossignol JM (1989) Biosynthesis of hepatitis B virus e antigen: directed mutagenesis of the putative aspartyl protease site. J Virol 63: 5497–5500

    PubMed  CAS  Google Scholar 

  • Kassianides C, Hoofnagle JH, Miller RH, Doo E, Ford H, Broder S, Mitsuya H (1989) Inhibition of duck hepatitis B virus replication by 2′,3′-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology 97: 1275–1280

    PubMed  CAS  Google Scholar 

  • Korba BE, Cote PJ, Shapiro M, Purcell RH, Gerin JL (1989) In vitro production of infectious woodchuck hepatitis virus by lipopolysaccaride-stimulated peripheral blood lymphocytes. J Infect Dis 160: 572–576

    Article  PubMed  CAS  Google Scholar 

  • Lee B, Luo WX, Suzuki S, Robins MJ, Tyrrell DL (1989) In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother 33: 336–339

    PubMed  CAS  Google Scholar 

  • Letsinger RL, Zhang GR, Sun DK, Ikeuchi T, Sarin PS (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci USA 86: 6553–6556

    Article  PubMed  CAS  Google Scholar 

  • Lever AM (1988) Treatment of the chronic hepatitis B virus carrier state. J Infect 16: 221–229

    Article  PubMed  CAS  Google Scholar 

  • Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS (1983) Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 84: 216–219

    PubMed  CAS  Google Scholar 

  • Lien JM, Aldrich CE, Mason WS (1986) Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis. J Virol 57: 229–236

    PubMed  CAS  Google Scholar 

  • Marion PL (1988) Use of animal models to study hepatitis B virus. Prog Med Virol 35: 43–75

    PubMed  CAS  Google Scholar 

  • Mason WS, Lien J-M, Petcu DJ, Coates L, London WT, O’Connell A, Aldrich C, Custer RP (1987) in vivo and in vitro studies on duck hepatitis B virus replication. In: Hepadna viruses. UCLA symposia on molecular and cellular biology, new series. Liss, New York

    Google Scholar 

  • Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S (1989) Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA 86: 4244–4248

    Article  PubMed  CAS  Google Scholar 

  • Maynard JE, Kane MA, Hadler SC (1989) Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization. Rev Infect Dis 11: S574–S578

    Article  PubMed  Google Scholar 

  • Meek TD, Lambert DM, Dreyer GB, Carr TJ, Tomaszek TA Jr, Moore ML, Strickler JE, Debouck C, Hyland LJ, Matthews TJ, Metcalf BW, Petteway SR (1990) Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343: 90–92

    Article  PubMed  CAS  Google Scholar 

  • Miller RH (1987) Proteolytic self-cleavage of hepatitis B virus core protein may generate serum e antigen. Science 236: 722–725

    Article  PubMed  CAS  Google Scholar 

  • Nagaya T, Nakamura T, Tokino T, Tsurimoto T, Imai M, Mayumi T, Kamino K, Yamamura K, Matsubara K (1987) The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1: 773–782

    Article  PubMed  CAS  Google Scholar 

  • Nassal M, Galle PR, Schaller H (1989) Proteaselike sequence in hepatitis B virus core antigen is not required for e antigen generation and may not be part of an aspartic acid-type protease. J Virol 63: 2598–2604

    PubMed  CAS  Google Scholar 

  • Neurath AR, Kent SBH (1988) The pre-S region of hepadnavirus envelope proteins. Adv Virus Res 34:65–142

    Article  PubMed  CAS  Google Scholar 

  • Nordenfeit E, Widell A, Hansson BG, Lofgren B, Moller-Nielsen C, Oberg B (1982) No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production. Acta Pathol Microbiol Immunol Scand 90: 449–451

    Google Scholar 

  • Ochiya T, Tsurimoto T, Ueda K, Okubo K, Shiozawa M, Matsubara K (1989) An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. Proc Natl Acad Sci USA 86: 1875–1879

    Article  PubMed  CAS  Google Scholar 

  • Peeples ME, Komai K, Radek R, Bankowski MJ (1987) A cultured cell receptor for the small S protein of hepatitis B virus. Virology 160: 135–142

    Article  PubMed  CAS  Google Scholar 

  • Persing DH, Varmus HE, Ganem D (1987) The preS1 protein of hepatitis B virus is acylated a† its amino terminus with myristic acid. J Virol 61: 1672–1677

    PubMed  CAS  Google Scholar 

  • Petcu DJ, Aldrich CE, Coates L, Taylor JM, Mason WS (1988) Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology 167: 385–392

    PubMed  CAS  Google Scholar 

  • Pontisso P, Petit M-A, Bankowski MJ, Peeples ME (1989) Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin for the pre-S2 region. J Virol 63: 1981–1988

    PubMed  CAS  Google Scholar 

  • Price PM, Banerjee R, Acs B (1989) Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2′-deoxyguanosine. Proc Natl Acad Sci USA 86: 8541–8544

    Article  PubMed  CAS  Google Scholar 

  • Pugh JC, Summers JW (1989) Infection and uptake of duck hepatitis B virus by duck hepatocytes maintained in the presence of dimethyl sulfoxide. Virology 172: 564–572

    Article  PubMed  CAS  Google Scholar 

  • Pugh J, Zweidler A, Summers J (1989) Characterization of the major duck hepatitis B virus core particle protein. J Virol 63: 1371–1376

    PubMed  CAS  Google Scholar 

  • Radziwill G, Tucker W, Schaller H (1990) Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 64: 613–620

    PubMed  CAS  Google Scholar 

  • Ranade VV (1989) Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J Clin Pharmacol 29: 685–694

    PubMed  CAS  Google Scholar 

  • Rijntjes PJ, Moshage HJ, Yap SH (1988) In vitro infection of primary cultures of cryopreserved adult human hepatocytes with hepatitis B virus. Virus Res 10: 95–109

    Article  PubMed  CAS  Google Scholar 

  • Sacks SL, Scullard GH, Pollard RB et al. (1982) Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrob Agents Chemother 21: 93–100

    PubMed  CAS  Google Scholar 

  • Samuel CE (1988) Mechanisms of the antiviral action of interferons. Prog Nucleic Acid Res Mol Biol 35: 27–72

    Article  PubMed  CAS  Google Scholar 

  • Schlicht HJ, Bartenschlager R, Schaller H (1989) The duck hepatitis B virus core protein contains a highly phosphorylated C terminus that is essential for replication but not for RNA packaging. J Virol 63: 2995–3000

    PubMed  CAS  Google Scholar 

  • Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, Merigan TC (1981) Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 143: 772–783

    Article  PubMed  CAS  Google Scholar 

  • Seeger C, Ganem D, Varmus HE (1986) Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 232: 477–484

    Article  PubMed  CAS  Google Scholar 

  • Sells MA, Chen ML, Acs G (1987) Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84: 1005–1009

    Article  PubMed  CAS  Google Scholar 

  • Sherker AH, Hirota K, Omata M, Okuda K (1986) Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 91: 818–824

    PubMed  CAS  Google Scholar 

  • Smee DF, Knight SS, Duke AE, Robinson WS, Matthews TR, Marion PL (1985) Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl) guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase. Antimicrob Agents Chemother 27: 277–279

    PubMed  CAS  Google Scholar 

  • Smith CC, Aurelian L, Reddy MP, Miller PS, Ts’o PO (1986) Antiviral effect of an oligo (nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc Natl Acad Sci USA 83: 2787–2791

    Article  PubMed  CAS  Google Scholar 

  • Stein CA, Cohen JS (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 48: 2659–2668

    PubMed  CAS  Google Scholar 

  • Su TS, Lai CJ, Huang JL, Lin LH, Yauk YK, Chang CM, Lo SJ, Han SH (1989) Hepatitis B virus transcript produced by RNA splicing. J Virol 63: 4011–4018

    PubMed  CAS  Google Scholar 

  • Sureau C, Romet-Lemonne J-L, Mullins Jl, Essex M (1986) Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell 47: 37–47

    Article  PubMed  CAS  Google Scholar 

  • Tsiquaye KN, Collins P, Zuckerman AJ (1986) Antiviral activity of the polybasic anion, suramin and acyclovir in Hepadna virus infection. J Antimicrob Chemother 18: 223–228

    PubMed  CAS  Google Scholar 

  • Tuttleman JS, Pourcel C, Summers J (1986a) Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47: 451–460

    Article  PubMed  CAS  Google Scholar 

  • Tuttleman JS, Pugh JC, Summers JW (1986b) In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol 58:17–25

    PubMed  CAS  Google Scholar 

  • Twu JS, Robinson WS (1989) Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc Natl Acad Sci USA 86: 2046–2050

    Article  PubMed  CAS  Google Scholar 

  • Ueda K, Tsurimoto T, Nagahata T, Chisaka O, Matsubara K (1989) An in vitro system for screening anti-hepatitis B virus drugs. Virology 169: 213–216

    Article  PubMed  CAS  Google Scholar 

  • Venkateswaran PS, Millman I, Blumberg BS (1987) Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA 84: 274–278

    Article  PubMed  CAS  Google Scholar 

  • Viola LA, Barrison IA, Coleman JC, Paradinas FJ, Murray-Lyon IM (1981) The HBe antigen-antibody system and its relationship to clinical and laboratory findings in 100 chronic HBsAg carriers in Great Britain. J. Med Virol 8: 169–175

    PubMed  CAS  Google Scholar 

  • Will H, Reiser W, Weimer T, Pfaff E, Buscher M, Sprengel R, Cattaneo R, Schaller H (1987) Replication strategy of human hepatitis B virus. J Virol 61: 904–911

    PubMed  CAS  Google Scholar 

  • Wu T-T, Coates L, Aldrich CE, Summers J, Mason WS (1990) In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175 (in press)

    Google Scholar 

  • Yaginuma K, Shirakata Y, Kobayashi M, Koike K (1987) Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci USA 84: 2678–2682

    Article  PubMed  CAS  Google Scholar 

  • Zerial A, Thuong NT, Helene C (1987) Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Res 15: 9909–9919

    Article  PubMed  CAS  Google Scholar 

  • Zuckerman AJ (1987) Screening of antiviral drugs for hepadna virus infection in Pekin ducks: a review. J Virol Methods 17:119–126

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine, Stanford, 94305, CA, USA

    P. L. Marion

Authors
  1. P. L. Marion
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA, 19111, USA

    William S. Mason  & Christoph Seeger  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin·Heidelberg

About this chapter

Cite this chapter

Marion, P.L. (1991). Development of Antiviral Therapy for Chronic Infection with Hepatitis B Virus. In: Mason, W.S., Seeger, C. (eds) Hepadnaviruses. Current Topics in Microbiology and Immunology, vol 168. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76015-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76015-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76017-4

  • Online ISBN: 978-3-642-76015-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation